The Online Investor
Daily M&A
Contrarian Outlook
Stock Option Ideas
Preferred Stock Newsletter
ChartZero.com
Biotechnology M&A image Biotechnology M&A » By The Online Investor Staff, updated Thu., May. 9, 9:46 AM Recent mergers and acquisitions in the Biotechnology M&A category.

Slide #66. Illumina, Inc. Verinata Health

Acquirer: Illumina, Inc. (NASDAQ:ILMN)
Acquiree: Verinata Health
Details: Illumina, Inc. (NASDAQ:ILMN) today announced it has completed its previously announced acquisition of Verinata Health, Inc., a leading provider of non-invasive tests for the early identification of fetal chromosomal abnormalities. As of the close, Verinata Health became a wholly owned subsidiary of Illumina.

Illumina is engaged in sequencing- and array-based solutions for genetic and genomic analysis. Co.'s products and services enable the adoption of genomic solutions in research and clinical settings. Co.'s principal products, services, and technologies are: sequencing, which includes Deoxyribonucleic acid (DNA) sequencing, a process of determining the order of nucleotide bases (A, C, G, or T) in a DNA sample; arrays, which are used for a range of DNA and RNA analysis applications; consumables, which Co. has developed various library preparation and sequencing kits; and services, which provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services.

ILMN SEC Filing Email Alerts Service


Open the ILMN Page at The Online Investor »

Company Name:  Illumina Inc
Stock buyback:  ILMN buyback
Website:  www.illumina.com
Sector:  Biotechnology
Number of ETFs Holding ILMN:  102
Total Market Value Held by ETFs:  $3.13B
Total Market Capitalization:  $18.95B
% of Market Cap. Held by ETFs:  16.52%
 

Open the ILMN Page at The Online Investor (in a new window) »

May 9, 2024    9:46 AM Eastern
Quotes delayed 20 minutes

Email EnvelopeFree ILMN Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Buy (2.78 out of 4)
16th percentile
(ranked lower than approx. 84% of all stocks covered)

Analysts' Target Price:
ILMN Stock Forecast

Based on Zacks ABR data;
powered by Xignite

Biotechnology M&A - Slide 66 of 83 | www.TheOnlineInvestor.com | Copyright © 1998 - 2024, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.